Original Application for an 
Investigational Device Exemption 
19 July 2017
Subcutaneous Tibial Nerve Stimulation 
for Urgency Urinar y Incontinence 
Device Name:  [CONTACT_11714] (Electroceutical Coin) 
Protocol Number: 
IDE Number: 111-3186  
G170028
[STUDY_ID_REMOVED]
Sponsor & Manufacturer: Valencia Technologies Corporati on 
[ADDRESS_907954] 
Valencia, CA [ZIP_CODE] 
[LOCATION_002] 
Principal Investigators: Scott MacDiarmid, M.D. 
CONFIDENTIAL  
Document Number 111-3186  Rev. 1.6 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 2 of 83 TABLE OF CONTENTS  
1 INTRODUCTION  ................................ ................................ ................................ ................................ ................  5 
 NAME, ADDRESS , AND SIGNATURE [CONTACT_11715]  ................................ ................................ ................................ ..... 5 
 OVERVIEW  ................................ ................................ ................................ ................................ ................................ ...... 5 
2 REPORT OF PRIOR INVESTIGATIONS  ................................ ................................ ................................ ....... 7 
 PRIOR PUBLICATIONS OF ANIMAL STUDIES  ................................ ................................ ................................ ..............  7 
 HUMAN STUDIES  ................................ ................................ ................................ ................................ ...........................  8 
2-2-1 Prior Publications of Tibial Nerve Stimulation for Overactive Bladder  ................................ .........  8 
2-2-2 Prior Studies of the Valencia Technologies eCoin System  ................................ ................................ .... 9 
 EXECUTIVE SUMMARY OF NON-CLINICAL STUDIES ................................ ................................ ...............................  11 
2-3-1 Bench Testing - eCoin Device  ................................ ................................ ................................ ........................  11 
2-3-2 Bench Testing External Controller  ................................ ................................ ................................ .............  15 
2-3-3 MR Compatibility  ................................ ................................ ................................ ................................ ...............  16 
2-3-4 Electrical Safety and Electromagnetic Compatibility  ................................ ................................ .........  17 
2-3-5 Electrical Safety and EMC External Controller  ................................ ................................ ......................  18 
2-3-6 Software eCoin Device (209 -1035, 209 -1061, 303 -1122)  ................................ ................................ . 18 
2-3-7 Software External Controller (207 -1541 , 303 -1122)  ................................ ................................ ..........  18 
2-3-8 Biocompatibility  ................................ ................................ ................................ ................................ .................  19 
2-3-9 Particulate (Nelson Lab Number 884283 -01) ................................ ................................ .......................  21 
2-3-10 Sterility (20 02-1206)  ................................ ................................ ................................ ................................ .. 21 
2-3-11 Packaging (202 -1254; Westpak 225 -15-0053A)  ................................ ................................ .............  21 
2-3-12 Shelf Life (202 -1254; Westpak 225 -15-0053B, 225 -15-0053C)  ................................ ................  [ADDRESS_907955] Activation Follow -up Procedure ................................ ................................ ................................ ... 32 
3-4-11 Escape Procedure  ................................ ................................ ................................ ................................ .........  32 
 STUDY ENDPOINTS  ................................ ................................ ................................ ................................ ......................  32 
3-5-1 Primary Outcome Measures  ................................ ................................ ................................ ..........................  32 
3-5-2 Key Secondary Outcome Measure  ................................ ................................ ................................ ...............  32 
3-5-3 Exploratory Secondary Outcome Measures  ................................ ................................ ............................  32 
 RATIONALE FOR THE SELECTION OF OUTCOME MEASURES AND STUDY DESIGN  ................................ ............  33 
 RISK ANALYSIS ................................ ................................ ................................ ................................ .............................  34 
3-7-1 Overview ................................ ................................ ................................ ................................ ................................  34 
3-7-2 Description of Patient Population  ................................ ................................ ................................ ...............  35 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 3 of 83 3-7-3 Justification for Investigation  ................................ ................................ ................................ .......................  35 
3-7-4 Additional Safety Profile Information  ................................ ................................ ................................ ....... 35 
3-7-5 Standards Conformance Demonstrating Safety  ................................ ................................ ....................  37 
 DESCRIPTION OF THE DEVICE  ................................ ................................ ................................ ................................ ... 38 
3-8-1 Components  ................................ ................................ ................................ ................................ .........................  38 
3-8-2 Stimulation Settings/Parameters  ................................ ................................ ................................ ...............  [ADDRESS_907956] Withdrawal & Termination  ................................ ................................ ................................ ...........  [ADDRESS_907957] / Ethics Committees  ................................ ................................ ............  [ADDRESS_907958] Compensation  ................................ ................................ ................................ ................................  55 
 STUDY TIMETABLE  ................................ ................................ ................................ ................................ ......................  55 
4 ATTACHMENTS  ................................ ................................ ................................ ................................ ..............  56 
 3-DAY VOIDING DIARY  ................................ ................................ ................................ ................................ ...............  57 
 MANUALS , AND LABELS  ................................ ................................ ................................ ................................ .............  58 
 INVESTIGATOR ’S BROCHURE  ................................ ................................ ................................ ................................ ..... [ADDRESS_907959] ................................ ................................ ................................ ................................  63 
 CASE REPORT FORMS  ................................ ................................ ................................ ................................ .................  64 
 ADVERSE EVENT FORM  ................................ ................................ ................................ ................................ ..............  65 
 DSMB  CHARTER  ................................ ................................ ................................ ................................ .........................  66 
 OUS  STUDY FOR HYPERTENSION PROTOCOL  ................................ ................................ ................................ .........  67 
 OUS  STUDY FOR HYPERTENSION CRF S FOR INFECTIONS  ................................ ................................ ...................  68 
 OUS  STUDY FOR HYPERTENSION DSMB  LETTER RECOMMENDING SUSPENSION OF IMPLANTATION AT 
SITE 12 69 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 4 of 83 
 SNS  RISK ASSESSMENT (110 -1493)  ................................ ................................ ................................ ....................  [ADDRESS_907960] OF INVESTIGATORS  ................................ ................................ ................................ ................................ .............  81 
 303 -1122  SOFTWARE DESIGN SPECIFICATION SNS  ................................ ................................ ..........................  82 
 BIOCOMPATIBILITY REPORTS  ................................ ................................ ................................ ................................ ... 83 
  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 5 of 83 1 Introduction  
 Name , Address, and Signature  [CONTACT_11716]:      Stacy Chambliss  
 
Title:         Chief of Scientific Review  
            
Address:  Valencia Technologies Corporation   
[ADDRESS_907961]  
Valencia, CA [ZIP_CODE]  
[LOCATION_002]  
 
 
Phone:  +[PHONE_12899] ext. 1002  
 
Fax: +1 (661) 775 -1411  
 
Email:  schambliss@va lenciatechnologies.com  
 
 
Signature [CONTACT_790] :_________ ________ __________ Date: ____________  
 Overview  
Overactive bladder (OAB) is a clinical diagnosis characterized by [CONTACT_11647], frequency, nocturia, and urgency 
incontinence. Urinary incontinence is a prevalent condition that markedly impacts 
quality of life affecting both men and  women (1). In population based studies, the 
prevalence  of OAB ranges from 7 % to 27% in men, and 9% to 43% in women (2-9). 
However, urgency urinary incontinence, characterized by [CONTACT_672000] a sudden compelling desire to void, is more common in women.  
Because urgency urinary incontinence can be difficult to distinguish from stress urinary 
incontinence, total inc ontinence epi[INVESTIGATOR_671985]. Suffering from unpredictable loss of urine and associated odor or related 
symptoms, the burden on quality of life is well documented .  
While physical therapy and surgery are relatively ef fective treatments for stress urinary 
incontinence, disorders of the detrusor muscle and/or neural regulation of the lower 
urinary tract system remain quite challenging to treat well . There are a number of 
treatments including first line behavioral therapi [INVESTIGATOR_11609] (anti -
muscarinics or oral β3-adrenoceptor agonists) , but many patients remain in poor control.  
For those not well treated by [CONTACT_11648], or intolerant of 
medications, percutaneous tibial nerve stimulat ion (PTNS) as well as sacral nerve 
stimulation (SNS) are approved for marketing  by [CONTACT_672001] (NICE) in the [LOCATION_008] and by [CONTACT_53010] a nd Drug 
Administration in the [LOCATION_002] . In the US, PTNS is cle ared for treatment of 
overactive bladder and the associated symptoms of urinary frequency, urinary urgency 
and urinary urge incontinence .  Furthermore,  a category I CPT code was approved by 
 
[CONTACT_672002]     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 6 of 83 the Centers for Medicare and Medicaid Services (effective Jan. 1, 2011). Percutaneous 
tibial nerve stimulation, described by [CONTACT_672003] 1990s, has been documented in a 
large number of medium sized clinical studies for the treatment of overactive bladder.  
For PTNS, given the need for mainten ance therapy over the  long-term (10), the expense 
of such maintenance visits,  and waning efficacy of the therapy  when conducted in the 
home  (11), the use of a  tiny fully -implantable device is likely to have advantages in 
implementation.   Such advantages may include automated c ompliance, lower cost over 
device life compared with long term visit costs, and improved efficacy through accurate 
device placement by [CONTACT_672004].  
1. Burgio  KL, Locher JL,  Goode  PS, et al. Behavioral  vs drug treatment  for 
urge urinary  incontinence in older women: a  randomized  controlled  trial. 
Jama  1998;280:1995 -2000.  
2. Choo MS, Ku JH, Lee JB et al: Cross -cultural differences for adapting 
overactive bladder symptoms: results of an epi[INVESTIGATOR_53069] c survey in Korea. 
World J Uro 2007; 25: 505.  
3. Corcos J and Schick E: Prevalence of overactive bladder and incontinence 
in Canada. Can J Urol 2004; 11: 2278.  
4. Coyne KS, Sexton CC, Vats V et al: National community prevalence of 
overactive bladder in the Uni ted States stratified by [CONTACT_11651]. Urology 
2011; 77: 1081.  
5. Tikkinen, KA, Auvinen A, Tiitinen A. et al: Reproductive factors associated 
with nocturia and urinary urgency inin women: A population -based study in 
Finland. Am J Obstet Gynecol 2008: 199: 153 e1.  
6. Irwin DE, Milsom I, Hunskaar S et al: Population -based survey of urinary 
incontinence, overactive bladder, and other lower urinary tract symptoms in 
five countries: Results of the EPIC study. Eur Urol 2006; 50: 1306.  
7. Stewart WF, Van Rooyen JB, Cundiff GW et al: Prevalence and burden of 
overactive bladder in the [LOCATION_002]. World J Uro 2003; 20: 327.  
8. Herschorn S, Gajewski J, Schulz J, et al: A population -based study of 
urinary symptoms and incontinence: The Canadian  Urinary Bladder Survery. 
BJU Int 2008; 101; 52.  
9. Milsom I, Abrams P, Cardozo L et al: How widespread are the symptoms of 
an overactive bladder and how are they managed? A population -based 
prevalence study. BJU Intl 2001; 87: 760.  
10. Yoong, Wai, et al. "Neuro modulative treatment with percutaneous tibial nerve 
stimulation for intractable detrusor instability: outcomes following a shortened 6 ‐
week protocol."  BJU international  106.11 (2010): 1673 -1676.  
11. van der Pal F, van Balken MR, Heesakkers  JP, et al: Percutane ous tibial 
nerve stimulation in the treatment of refractory overactive bladder syndrome: 
is maintenance treatment necessary? BJU Int 2006, 97(3):547 –550. 
 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-[ADDRESS_907962] demonstrated in a cat model that stimulation of the cut end s of dorsal 
spi[INVESTIGATOR_671986] ( 12).  The hypothesis for t his effect was an action 
of neural circuitry in the forebrain, as intercollicular decerebration or thoracic spi[INVESTIGATOR_671987] ( 13).  Late r, in 1980, Sato et al. verified that electrical 
stimulation of afferent nerves to hind limb muscles, but not cutaneous afferents, inhibited 
reflex bladder acti vity in the anesthetized cat ( 14).  Three years later, McGuire and 
Morrissey used electrical stimulation of the hindquarter nerves to treat detrusor instability 
in spi[INVESTIGATOR_671988] 16 patients ( 15).  Next, case studies were conducted and then a 
number of randomized, controlled trials.  
 
The tibial nerve is a mixed nerve comprised of sensory and motor nerve fibers. It is by 
[CONTACT_622234].  It is the large diameter so matic afferent 
fibers of the tibial nerve that cause inhibition of bladder activity  by [CONTACT_672005][INVESTIGATOR_11614]. Such is 
confirmed by [CONTACT_11655] ( 14). Neuromodulation of the tibial 
nerve is presumed to improve or restore normal control of an imbalanced voiding reflex 
by [CONTACT_11656] ( 12, 17).  Thus, the  therapy aims to cause detrusor 
inhibition by [CONTACT_11657].  Interestingly, it 
appears that the same spi[INVESTIGATOR_418847] (L4 -S3) are targeted by [CONTACT_672006].  It appears that stimulation of the sacral roots, sacral nerve, 
pudendal nerve and ti bial nerve all affect central components of the neural circuits 
controlling the bladder, yet we can deduce some distinctions in the action.  That is,  a 
study by [CONTACT_672007] a persisten t post -stimulation inhibition and increase of bladder capacity  (18) that 
is replicated by [CONTACT_11659] , yet the effects of sacral nerve 
stimul ation are shown to go away  once stimulation is stopped ( 19).  
 
As the bladder is controlled by [CONTACT_11660], parasympathetic, and somatic nervous 
systems that are regulated by [CONTACT_11661] (PMC), it is likely that tibial 
nerve stimulation acts on the PMC, either via the pelvic nerve or pudendal nerve or both. 
Bladder contraction (micturition) is controlled via the pelvic nerve (S2 -S4) and 
continence is controlled via the hypogastric nerve (T10 -L2) and the pudendal nerve (L4 -
S3); it is thereby [CONTACT_672008] s of the tibial 
nerve , with spi[INVESTIGATOR_11616] L4 -S3, finds its effect on the bladder via either the pelvic or 
the pudendal nerve.  
12. McPherson A. The effects of somatic stimuli on the bladder in the cat. J Physiol. 
1966;185(1):185 –96.  
13. McPherson A. Vesico -somatic reflexes in the chronic spi[INVESTIGATOR_11617]. J Physiol. 
1966;185(1):197 –204.PubMed  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-[ADDRESS_907963]. 1983;7:351 –62.PubMed CrossRef  
15. McGuire EJ, Zhang SC, Horwinski ER, Lytton B. Treatment of motor and sensory 
detrusor instability by [CONTACT_11662]. J Urol. 1983;129(1):78 –9.  
16. van der Pal, F., M. van Balken, and J. Heesakkers. "Maintenance perc utaneous 
tibial nerve stimulation (PTNS) treatment in successfully treated patients with 
refractory overactive bladder syndrome: a necessity." Eur Urol  47.Suppl 4 (2005): 
144. 
17. Vandoninck, Vera, et al. "Posterior tibial nerve stimulation in the treatment of 
urge incontinence."  Neurourology and urodynamics  22.1 (2003): 17 -23. 
18. Tai C, Shen B, Chen M, Wang J, Roppolo JR, de Groat WC. Prolonged 
poststimulation inhibition of bladder activity induced by [CONTACT_11663]. Am J Physiol Ren Physiol. 2011;300(2):F385 –92. 
doi:10.1152/ajprenal.[ZIP_CODE].[ADDRESS_907964] Rev. 
2009; Suppl 2:CD004202. doi: 10.1002/14651858.CD004202.pub2  
20. Oerlemans, De nnis JAJ, and Philip EV Van Kerrebroeck. "Sacral nerve 
stimulation for neuromodulation of the lower urinary tract."  Continence . Springer 
London, 2009. [ADDRESS_907965] described by [CONTACT_672009]. (21) and more recent authors such as Govier  et al. 
(22), van Balken  et al. (23) and Vandoninck  et al. (24) have confirmed a 60 –80% 
positive response  rate after 12 weekly tre atments with  percut aneous tibial nerve 
stimulation.  According to a me ta-analysis by [CONTACT_11665]. ( 25), level 1 evidence is 
available and supportive of the safety and efficacy of tibial nerve stimul ation for 
overactive bladder .  Data available on the safety of percutaneous tibial nerve stimulation 
shows no major concerns for safety.  For example, in the 24 month follow up study to the 
SUmiT trial, the authors find there were no reported treatment related adverse events in 
the 5 0 subjects through 24 months ( 26).  Four subjects reported five adverse events with 
unknown causes (UTI, pulling feeling on feet, bladder pressure, pi [INVESTIGATOR_671989] d slow 
stream) . 
21. McGuire, E. J., et al. "Treatment of motor and sensory detrusor instability by 
[CONTACT_11662]."  The Journal of urology  129.1 (1983): 78 -79. 
22. Govier, Fred E ., et al. "Percutaneous afferent neuromodulation for the refractory 
overactive  bladder: results of a multicenter study."  The Journal of urology  165.4 
(2001): 1193 -1198.  
23. van Balken, Michael R ., et al. "Posterior tibial nerve stimulation as 
neuromodulative treatment of lower urinary tract dysfunction."  The Journal of 
urology  166.3 (20 01): 914 -918. 
24. Vandoninck, Vera, et al. "Posterior tibial nerve stimulation in the treatment of 
urge incontinence."  Neurourology and urodynamics  22.1 (2003): 17 -23. 
25. Gaziev, Gabriele, et al. "Percutaneous tibial nerve stimulation (PTNS) efficacy in 
the treatment of lower urinary tract dysfunctions: a systematic review."  BMC 
urology  13.1 (2013): 1.  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 9 of 83 26. Peters, Kenneth M., et al. "Randomized trial of percutaneous tibial nerve 
stimulation versus Sham efficacy in the treatment of overactive bladder 
syndrome: res ults from the SUmiT trial."  The Journal of urology  183.4 (2010): 
1438 -1443.  
27. Finazzi -Agrò, Enrico, et al. "Percutaneous tibial nerve stimulation effects on 
detrusor overactivity incontinence are not due to a placebo effect: a randomized, 
double -blind, place bo controlled trial."  The Journal of urology 184.5 (2010): 2001 -
2006.  
28. Amarenco, G., et al. "Urodynamic effect of acute transcutaneous posterior tibial 
nerve stimulation in overactive bladder."  The Journal of urology  169.6 (2003): 
2210 -2215.  
29. Peters, Kenneth M., et al. "Sustained therapeutic effects of percutaneous tibial 
nerve stimulation: 24 ‐month results of the STEP study."  Neurourology and 
urodynamics  32.1 (2013): [ADDRESS_907966] implant and le d to the explant of the 
device. Three out of the fou r infections were from  one clinical center  which was 
subsequently shut down at the recommendation of the DSMB. One additional explant of 
a device occurred at this same center due to an unconfirmed infection. All remaining 
Adverse Events  were thought to be unrelated to the device or therapy.  
The case report forms for the four reported infections are in Attachment  4-12.  In 
addition, a fifth case report form is includ ed for what the DSMB regarded as an infection 
leading to explant that was not appropriately handled by [CONTACT_11668], Canada  
(Site 12) . 
The five subject adverse events with infection or explant can be summarized as follows: 
12-005 reported moderate bilateral device infection resolved with antibiotics; 04 -008 
reported severe left arm infection treated initially with antibiotics, but ultimately resulting 
in explantation of device from the left arm; 14 -006 self-reported  mild small infection for a 
few da ys that resolved on its own; 12 -007 reported mild right forearm infection that 
resolved with antibiotics; and 12 -004 reported middle finger cellulitis initially treated with 
antibiotics, but ultimately resulting in explantation of device from the right arm .  The 
corresponding adverse event logs, organized according to patient number, are enclosed.  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 10 of 83 The DSMB investigation into the higher than average infection at Site 12 found that the 
Site was not timely in its filing of adverse event reports; and pointed out that the AE on 
12-004 stated that the patient’s swollen middle finger was observed on the very day of 
implantation.  After discussions with site [ADDRESS_907967] ion rate.  The DSMB 
recommended suspension of implantation at Site 12 (see attached letter from DSMB – 
Attachment  4-13).  After discussions with the Principal Inves tigator at Site 12, the 
Company decided to suspend indefinitely any further implantations at Site 12.  
2-2-2-[ADDRESS_907968] been no de vice related serious adverse 
events.   
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 11 of 83 
 Executive  Summary of Non -Clinical Studies  
Preclinical testing of the eCoin subcutaneous neuromodulation system has been 
performed to assure conformance to the design specifications.  
The eCoin subcutaneous neuromodulation system was developed under an ISO 
[ZIP_CODE]:2012 compliant risk management process to identify potential harms and to 
eliminate risk or reduce risks to an acceptable level.  
2-3-1 Bench Testing - eCoin Device  
The eCoin device is designed to be complia nt with all applicable clauses of ISO [ZIP_CODE] -
1:2014 Implants for surgery – Active implantable medical devices – Part 1: General 
requirements for safety, marking and for information to be provided by [CONTACT_672010] [ZIP_CODE] -3:2008 Active implantable m edical devices -- Part 3: Implantable 
neurostimulators . 
2-3-1-1 Stimulus Output (207 -1093 2.2.1 -2.2.5, 2.3.1; 207 -1082 2.1 -2.5, 2.8)  
The stimulation output pulse amplitude, current regulation (at loads of 300, 600, 1000, 
1500, and 2500 Ohms), pulse width and puls e rate of the eCoin device were verified at 
room temperature, 20 °C, and 45 °C and over battery voltages of 2.7 V, 3 V and 3.2 V.  
Folder: “VOL_018_IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “004_207 -[ADDRESS_907969] Report.” Refer to 
Sections 2.2.1 -2.2.5 and 2.3.1.  
File: “003_207 -[ADDRESS_907970] Report.” Refer to 
Sections 2.1 -2.5 and 2.8.  
2-3-1-2 Internal Moisture (207 -1093 2.3.2, 2.3.3)  
Residual gas analysis was performed to verify the internal moisture of the hermetically 
sealed eCoin device is no more than 1.5%. This test was  repeated on eCoin devices 
after 24 hour water immersion at 80 °C water and a pressure of 2 atm.  
Folder: “VOL_018 IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “004_207 -[ADDRESS_907971] Report.” Refer to 
Sections 2.3.2 and 2.3.3.  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 12 of 83 2-3-1-3 Temperature Exposure (207 -1093 2.3.4, 202-1254 ) 
The eCoin d evice in a sterile pack passed final fu nctional test after one hour of 
temperature exposure at  -10 °C and 55 °C per ISO [ADDRESS_907972] after exposure to 
climatic co nditioning per ASTM D4332 -13. 
Folder : “VOL_018 IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “004_207 -[ADDRESS_907973] Report.” Refer to 
Section 2.3.4.   
Folder : “VOL_020_IDE Attachment 4-18 Sterile Packaging Validation 
Report ” 
File: “001_4.18 202 -1254 SNS Device Packaging Validation Report”  
2-3-1-4 Pressure Exposure (207 -1093 2.3.5)  
The eCoin device passed final functional test after one hour of pressure exposure at 70 
kPa and 150 kPa per ISO [ZIP_CODE] -1:2014 clause 25.  
Folder: “VOL_018 IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “004_207 -[ADDRESS_907974] Report.” Refer to 
Section 2.3.5.  
2-3-1-5 Random Vibration (207 -1093 2.3.7)  
The eCoin device passed final functional test after random vibration at 5 Hz to 500 Hz 
for 30 minutes in each of three mutually perpendicular axes per ISO [ZIP_CODE] -1:2014 
clause 23.2.   
Folder: “VOL_018 IDE Attachment 4-16 Design Verification and 
Validation Report s”  
File: “004_207 -[ADDRESS_907975] Report.” Refer to 
section 2.3.7.  
2-3-1-6 Mechanical Shock (207 -1093 2.3.8)   
The eCoin device passed final functional test after mechanical shock pe r ISO [ZIP_CODE] -
1:2014 clause 23.7 (1 ms duration 500 g half -sine).  
Folder: “VOL_018 IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “004_207 -[ADDRESS_907976] Report.” Refer to 
Section 2.3.8.  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-[ADDRESS_907977] (207 -1093 2.3.9)  
The eCoin device passed final functional test following a ten minute exposure to a force 
of 45 N applied to the top center of the device over an area of 0.5 cm squared.  
Folder: “VOL_018 IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “004_207 -[ADDRESS_907978] Report.” Refer to 
Section 2.3.9.   
2-3-1-8 Battery UL Testing (EA1821)  
The eCoin device battery passed testing per UL 1642 5th edition including short circuit 
(room temperature and 55 °C), abnormal charging, crush, impact, shock, vibration, 
heating, temperature cycling, low pressure and projectile.   
Folder: “VOL_018_IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “013_EA1821_RPT_Vale ncia CR1612_UL1642.”  
2-3-1-[ADDRESS_907979] (207 -1093 2.3.12)  
The eCoin device battery under an external short circuit fault condition was verified to 
generate less than a 2 °C temperature rise at the device surface when implanted 
subcutaneously ( ISO [ZIP_CODE] -3:2008 clause  17.1). 
Folder: “VOL_018 IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “004_207 -[ADDRESS_907980] Report.” Refer to 
Section 2.3.12.  
2-3-1-[ADDRESS_907981] (207 -1093 2.3.13)  
The eCoin device passed final functional test following a [ADDRESS_907982] delivering 10 V peak to peak between the anode and 
cathode approximating the signal from monopolar electrocautery applied no closer than 
25 cm from the eCoin device.  
Folder: “VOL_018 IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “004_207 -[ADDRESS_907983] Report.” Refe r to 
Section 2.3.13.  
 
 
 
 
 
 
 
 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-[ADDRESS_907984] (207 -1093 2.4.1)  
No corrosion of the eCoin case, feed through anode or cathode in phosphate buffered 
physiological saline at 37 °C was observed after continuous stimulation at maximum 
amplitude until battery depletion.  
Folder: “VOL_018 IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “004_207 -[ADDRESS_907985] Report.” Refer to 
Section 2.4.1.  
2-3-1-12 Battery Service Life and Elective Replacement (207 -1082 2.6, 2.7; 
201-1016, 201 -1111)  
The eCoin battery discharge current and accelerated battery discharge capacity at 37 °C 
were used to verify a [ADDRESS_907986] itude after a 12 month shelf life 
and a 1 year elective replacement at the maximum amplitude after a 12 month shelf life.  
Folder : “VOL_018_IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File 1: “003_207 -[ADDRESS_907987] Report.” Refer to 
Sections 2.6 and 2.7.  
File 2 : “022_ER 201 -1016 Rev 1 - CR1612  Battery”  
File 3: “0 23_ER 201 -1111 Rev 1 – CR1612 Battery Discharge 
Capacity RIR 419 -356”  
2-3-1-[ADDRESS_907988] (207 -1082 2.9)  
The eCoin electronics assembly (PCBA) passed final functional test following a highly 
accelerated life test (HALT) at 125 °C for  1000 hours while under power with a supply 
voltage of 3.2 volts.  
Folder: “VOL_018_IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “003_207 -[ADDRESS_907989] Report.” Re fer to 
Section 2.9.  
2-3-1-[ADDRESS_907990] (207 -1082 2.10)  
The eCoin electronics assembly (PCBA) passed final functional test following 
temperature cycling test per MIL -STD-883H Method 1010, Condition B (10 cycles, -55 
+0/-10 degrees Centigrade to 125 + 15/-0 degrees Centigrade, 10 minute dwell time 
minimum) . 
Folder: “VOL_018_IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “003_207 -[ADDRESS_907991] Report.” Refer to 
Section 2.10.  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 15 of 83 2-3-1-15 Laser Seam Weld Validation (202 -1436)  
The eCoin device laser seam weld process was validated (IQ, OQ, PQ) to demonstrate 
that it produces a reliable hermetic seam weld. Acceptance criteria included visual 
inspection, fine leak, gross leak and cross section for weld penetration.  
Folder: “VOL_018_IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “001_202 -1436 PVR SNS Device Seam Weld Top Cover and 
Feed thru Case.”  
2-3-2 Bench Testing External Controller  
The External Controller is designed to be compliant with all applicable clauses of AAMI / 
ANSI ES60601 -1:2005/(R) 2012 and A1:2012, c1:2009/(R) 2012 and a2:2010/(r) 2012 
(consolidated text)  Medical Electrical Equipment – Part 1: General requirements for 
basic safety and essential performance , IEC [ZIP_CODE] -1-2:2014 Medical electrical 
equipment – Part 1 -2: General requirements for basic safety and essential performance 
– Collateral standard: Electromagnetic disturbances  - Requ irements and tests . 
2-3-2-1 External Controller Output (207 -1541 4.2.1 - 4.2.8)  
The External Controller was verified to meet all output command and command data 
transmission and timing requirements.  
Folder: “VOL_018_IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “005_207 -1541 SNS External Controller Verification Tes t 
Report.” Refer to Sections 4.2.1 – 4.2.8.  
2-3-2-2 External  Controller Battery Discharge and Charge Time (207 -1541 
4.2.9, 4.2.10)   
The External Controller was verified to provide at least 7 days of standby [CONTACT_11671] 
15 minutes of transmit operation on a sing le battery charge. The External Controller 
charging with fully discharged battery was verified to complete within 6 hours.  
Folder: “VOL_018_IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “005_207 -[ADDRESS_907992] 
Report.” Refer to Sections 4.2.9 and 4.2.10.  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 16 of 83 2-3-2-3 External Controller Battery Safety Testing (RSZBHST 160325326, 
VTC-002A (IEC [ZIP_CODE] -1 4.3.8), 207 -1541 4.2.11 – 4.2.13, 4.2.15)  
The External Controller rechargeable Li -polymer battery has undergone safety testing 
and passed per IEC62133 :2012. In addition, the battery protection circuitry for over -
charging, over -discharge, and over -heating were verified to operate as specified.  Battery 
short -circuit protection was verified to operate as specified and also passed testing per 
IEC [ZIP_CODE] -1 4.3.8.  
Folder : “VOL_01 8_IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File 1: “014_005_RSZBHST 160325326.”  
File 2: “[ADDRESS_907993] ed Ec01 Remote.”  
File 3: “005_207 -[ADDRESS_907994] 
Report.” Refer to Sections 4.2.11 – 4.2.13 and 4.2.15.  
2-3-2-4 External Controll er Over -heat Shutdown (207 -1541 4.3.2, 4.3.3 )  
The External Controller has been verified to shut -down transmission if the temperature 
of the device exceeds 48 °C. 
Folder: “VOL_018_IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “005_207 -[ADDRESS_907995] 
Report.” Refer to Sections 4.3.2 and 4.3.3.  
2-3-2-5 External Controller IEC [ZIP_CODE] -1 (VTC -002A)  
The External Controller has passed applicable clauses of IEC [ZIP_CODE] -1: 2005 + CORR. 1 
(2006) + CORR. 2 (2007) + AM1 (2012) or IEC [ZIP_CODE] -1: 2012 . This includes clauses 5.7 
Humidity, 8.7 Leakage Current, 8.8.3 Dielectric Strength, [IP_ADDRESS] Enclosure Ball 
Pressure Test, 11.1.1 Excessive Temperatures, 11.6.1 Cleaning, Sterilization 
Disinfection and 15.3 Mechanical Strength (Push, Drop and Mould Stress Reli ef). 
Folder: “VOL_018_IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “021_External Controller Safety Testing VTC_002A IEC [ADDRESS_907996] ed Ec01 Remote”  
File Attachments: “017_External Controller Safety Testing VTC -
002A Attachment A Photographs;” “018_External Controller Safety 
Testing VTC -002A Attachment B S chematics;” “019_External 
Controller Safety Testing VTC -002A Attachment C Calibration;” and 
“020_External Controller Safety Testing VTC -002A Attachment D 
Specifications.”  
2-3-3 MR Compatibility  
The eCoin Subcutaneous Neuromodulation System has not been evaluate d for safety 
and compatibility in the MRI environment and is considered MRI unsafe. Patients with 
the eCoin implant should not undergo Magnetic Resonance Imaging (MRI).  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 17 of 83 2-3-4 Electrical Safety and Electromagnetic Compatibility  
2-3-4-1 Electromagnetic  Non-Ionizing Radiation Immunity ( SD72116479 -
0516 , 207 -1093 2.3.6)  
The eCoin device passed final functional test after and remained immune during 
exposure to e lectromagnetic non-Ionizing r adiation per ISO [ZIP_CODE] -3 Clause 27 . 
Folder : “VOL_018_IDE 4-16 Design Verification and Validation 
Report s” 
File 1: “016_SD72116479 -[ADDRESS_907997] Report.” Refer to Section 4.  
File 2: “004_207 -[ADDRESS_907998] Report.” Refer 
to Section 2.3.6.  
2-3-4-2 Current Leakage (207 -1093 2.3.10)  
The direct current leakage between the anode and cathode of the eCoi n was verified to 
be less than less than 0.75 microamperes / square millimeter of electrode surface per 
ISO [ZIP_CODE] -3 clause 16 .2. Notes: For a direct current leakage less than 1 microampere, 
the 4.0 ±0.2mm diameter cathode current density is less than 0.[ADDRESS_907999] case since it has a smaller surface area than the 
anode.  
Folder: “VOL_018 IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “004_207 -[ADDRESS_908000] Report.” Refer to 
Section 2.3.10.  
2-3-4-3 Insulation Leakage (207 -1093 2.3.11)  
After preconditioning by [CONTACT_11672] 9 g/l saline at 37 °C for at least 10 days, the 
eCoin insulation at maximum stimulation amplitude was verified to be greater than 3.3 
kOhm based on  no more than a 10% reduction in amplitude when the load is reduced 
from 600 Ohms to 300 Ohms ( measured greater than 30 kOhm) . 
Folder: “VOL_018 IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “004_207 -[ADDRESS_908001] Report.” Refer to 
Section 2.3.11.  
2-3-4-4 Electrostatic Discharge ( SD72116479 -0516) 
The eCoin device passed final functional test and demonstrated safe operation after 
exposure to electrostatic discharge per IEC [ZIP_CODE] -4-2 up to + [ADDRESS_908002] and up 
to + 15 kV air discharge.  
Folder: “VOL_018 IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “016_SD72116479 -[ADDRESS_908003] Report.” Refer to Section 3.1.  
 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 18 of 83 2-3-5 Electrical Safety and EMC External Controller  
2-3-5-1 Electromagnetic  Emissions and Non -Ionizing Radiation Immunity 
(SD72110544 -1015 )  
The External Controller has undergone testing and passed EMC emissions and 
immunity per IEC [ZIP_CODE] -1-2:2014. This includes radiated and conducted emissions per 
CISPR [ADDRESS_908004] transients per IEC [ZIP_CODE] -4-4, surge per IEC [ZIP_CODE] -4-5, RF common 
mode per IEC [ZIP_CODE] -4-6, power magnetic field of 30 A/m at 50Hz and 60 Hz per IEC 
[ZIP_CODE] -4-8 and voltage dip and interruptions per IEC [ZIP_CODE] -4-11. 
Folder: “VOL_018 IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “015_SD72110544 -[ADDRESS_908005] Report.” 
Refer to Section 3.  
2-3-6 Software eCoin Device (209 -1035, 209 -1061 , 303-1122 )   
The level of safety concern for the eCoin device firmware is Moderate since a failure or 
latent design flaw could directly result in a minor injury to the patient by [CONTACT_11673]/or the need for premature dev ice explant.  
Folder : “VOL_018 IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File 1: “006_209 -[ADDRESS_908006] Report”  
File 2: “007_209 -[ADDRESS_908007] Report” (plus 008_209 -
1061 Appendix A & 009_209 -1061 Appendix B)  
File 3: “ 024_209 -[ADDRESS_908008] Report 
OAB ”  
Folder : “VOL_028_IDE Attachment 4-26 303-1122 Software Design 
Specification SNS ” 
File: “001_4.26 303 -1122 Software Design Specification SNS.”  
2-3-7 Software External Controller (207 -1541 , 303 -1122 )  
The level of safety concern for the External Controller firmware is Minor since its function 
is limited such that a failure or design flaw is unlikely to cause any injury to the patient or 
operator. Verification and validation testing has been completed wi th all software design 
requirements met.  
Folder : “VOL_018 IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “005_207 -[ADDRESS_908009] 
Report.”  
Folder: “VOL_028_IDE Attachment 4-26 303-1122 Software Design 
Specification SNS ” 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 19 of 83 File: “001_4.26 303 -1122 Software Design Specification SNS.”  
2-3-8 Biocompatibility  
2-3-8-1 Cytotoxicity ISO [ZIP_CODE] -5 (PBL 14E0355G -M01G ) 
Based on the qualitative evaluation of cells exposed to eCoin test article extract, the 
eCoin test article was not considered to have a cytotoxic effect (no reactivity).  
Folder: “VOL_029 IDE Att achment 4-27 Biocompatibility Reports ” 
File: “001_Cytotoxicity Pacific BioLabs Study No. 14E0355G -M01G.”  
2-3-8-2 Sensitization ISO [ZIP_CODE] -10 (PBL 14H0049G -X01G )  
Under the conditions of the study, the eCoin test article did not elicit sensitization 
reactions.  
Folder: “VOL_029_IDE Attachment 4-27 Biocompatibility Reports ” 
File: “002_R eport Sensitization Pacific BioLabs Study No 
14H0049G -X01G.”  
2-3-8-3 Irritation ISO [ZIP_CODE] -10 (PBL 14H0048G -X01G )  
Based on erythema and edema scores, no irritation was noted with the eCoin test article 
when compared to control. Under the conditions of the study, t he eCoin test article met 
the requirements for the Intracutaneous (Intradermal) Reactivity Test.  
Folder: “VOL_029_IDE Attachment 4-27 Biocompatibility Reports ” 
File: “003_Irritation Pacific BioLabs Study No 14H0048G -X01G.”  
2-3-8-4 Acute Systemic Toxicity ISO [ZIP_CODE] -11 (PBL 14H0051G -X01G )   
None of the animals treated with eCoin test article extract exhibited a greater biological 
activity when compared to those treated with the control. Under the conditions of the 
study, the eCoin test article met the requirements of ISO [ZIP_CODE] -11. 
Folder: “VOL_029_IDE At tachment 4-27 Biocompatibility Reports ” 
File: “004_Acute Systemic Toxicity Pacific BioLabs Study No 
14H0051G -X01G.”  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 20 of 83 2-3-8-5 Sub-Chronic Systemic Toxicity 90 Day ISO [ZIP_CODE] -6 (PBL  16C0069G -
X01G)  
The results suggest that the device,  when implanted subcutaneously was well -tolerated 
in male and female Spragu e Dawley rats over a period of [ADDRESS_908010] group; a lump present near  the implant site (Animal #13) and 
right eye opacity (Animal # 12). The lesion near the implant site observed in one female 
animal was identified as M -adenocarcinoma of mammary gland and was considered 
incidental. The ocular changes observed in Animal #[ADDRESS_908011] article was comparable for male and female rats as characterized primarily by 
[CONTACT_11674], neovascularization, and cellular infiltrates .     
Folder: “VOL_029 IDE Attachment 4-27 Biocompatibility Reports ” 
File: “005_Sub -chronic Toxicity Pacific BioLabs Study No. 
16C0069G -X01G.”  
2-3-8-6 Genotoxicity ISO [ZIP_CODE] -3 (PBL 14E0349G -X01G , 16E0213G -X01G )  
Based on the criteria and conditions the Bacterial Mutagenicity Test (Ames Assay) used, 
the eCoin test article was considered non -mutagenic. In a ISO [ZIP_CODE] -3:[ADDRESS_908012] system.  
Folder: “VOL_029 IDE Attachment 4-27 Biocompatibility Reports ” 
File 1: “006_Genotoxicity AMES PBL No 14E0349G -X01G.”  
File 2: “007_Genotoxicity Mouse Lymphoma 16E0213G -X01G.”  
2-3-8-7 Implantation 90 Day ISO [ZIP_CODE] -6 (PBL 14E0356G -X01G )  
Under the conditions of the study, the eCoin test article was considered a non -irritant to 
the tissue as compared to the negative control article.  
Folder: “VOL_029 IDE Attachment 4-27 Biocompatibility Reports ” 
File: “008_Implantation Pacific BioLabs Study No. 14E0356G -X01G.”  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 21 of 83 2-3-8-8 Pyrogen - Material Mediated ISO [ZIP_CODE] -11 (PBL 16C0182G -X01G )  
The test was performed according to ISO [ZIP_CODE] -11 and USP <151> guidelines. All 
animals appeared healthy during the test and none of the tested rabbits exhibited 
individual increase in temperature greater or equal to 0.5 °C when compared to the 
control temperature. Based on criteria for this test, the test article meets USP <151> 
requirements for the absence of pyrogens  
Folder: “VOL_029_IDE Attachment 4-27 Biocompatibility Reports ” 
File: “009_Material -Mediated Pyrogenicity 16C0182G -X01G.”  
2-3-8-9 Ethylene Oxide Sterilization Residuals ISO [ZIP_CODE] -7 (Nelson 749416)  
The ethylene oxide residual for the eCoin device was less than 0.012 mg (1.2 
micrograms per centimeter squared of device surface area). The ethylene chlorohydrin 
residual for the eCoin device was less than 0.038 mg (3.8 micrograms per centi meter 
squared of device surface area). Both of these are within the ISO [ADDRESS_908013] limit.  
Folder: “ VOL_029_IDE Attachment 4-27 Biocompatibility Reports ” 
File: “ 010_EO Residuals 749416 8XL .” 
2-3-9 Particulate (Nelson Lab  Number 884283 -01)  
The eCoin device particulate counts meet requirements per ISO [ZIP_CODE] -1:2014 clause 
14.2.  
Folder: “VOL_018_IDE Attachment 4-16 Design Verification and 
Validation Report s” 
File: “010_884283 -S01 Particulate Test.”   
2-3-10 Sterility (20 02-1206)  
The eCoin device ethylene oxide sterilization process was validated per ISO [ZIP_CODE]  
using half cycle batch release approach using the over kill method (ISO [ZIP_CODE] -
1:2007(E) Annex B) . 
Folder: “VOL_019_IDE Attachment 4-17 Ethylene Oxide Sterilization 
Validation Reports ” 
File: “001_Ethylene Oxide Steril ization Validation Reports”  
2-3-11 Packaging (202 -1254; Westpak 225 -15-0053A)   
Validation of the eCoin device packaging demonstrated that the integrity of the final 
package is maintained under the severities of distribution, storage and handling. After 3x 
(worst  case) sterilization, baseline samples were tested for seal strength per ASTM 
F88M:2009 and seal integrity per ASTM F1886 -09. Remaining samples underwent 
climatic conditioning followed by [CONTACT_11675][INVESTIGATOR_11621] D4169 -14. 
Zero-aged samples w ere then tested for seal strength per ASTM F88M:2009 and seal 
integrity per ASTM F1886 -09. Remaining samples underwent accelerated and real time 
shelf -life aging (see 2-3-12). 
Folder : “VOL_020_IDE Attachment 4-18 Sterile Packaging Validation 
Report ” 
File 1: “001_202 -1254 SNS Device Packaging Valid ation Report.”  
File 2: “003_Appendix B Test Lab Report No 225 -15-0053A”   
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 22 of 83 2-3-12 Shelf Life (202 -1254; Westpak 225 -15-0053B, 225 -15-0053C)  
Accelerated and real time aging of the eCoin device and its packaging demonstrate d 
that the integrity of the final package  and device functionality is maintained over the 1 
year device shelf -life. Accelerated aging equivalent to a 13 month shelf life was 
completed per ASTM F1980 -07. Real -time aging for 13 months was completed at 
ambient conditions (approximately 25 °C and 50% relative humidity).  After aging, 
packaging samples were then  tested for seal strength per ASTM F88M:2009 and seal 
integrity  per ASTM F1886 -09 and the eCoin device underwent final functional testing.  
Folder : “VOL_020_IDE Attachment 4-18 Sterile Packaging Validation 
Report ” 
File 1: “001_ 202-1254 SN S Device Packaging Validation Report”  
File 2: “004_Appendix C Test Lab Report No 225 -15-0053B.”  
File 3: “005_Appendix C Test Lab Report No 225 -15-0053C 13 Month 
Real Time Aging of the SNS.”  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 23 of 83 3 Investigational  Plan   
 Purpose  
The investigation  is a feasibility  study of the safety and efficacy of the Valencia 
Technologies  eCoin system  in the treatment of urgency urinary incontinence in patients 
with refractory overactive bladder. The study will be completed in 16 months . 
The primary aims are  to evaluate the chang e in urge ncy incontinence epi[INVESTIGATOR_671990] 3 months  of tibial nerve stimulation therapy with eCoin and the safety of 
eCoin during the same period.  
 Summary  
This trial is a single arm, prospective  study of the safety and effectiveness of eCoin tibial 
nerve stimulation  in subjects with refractory overactive bladder  as defined by [CONTACT_672011] ( 30). The eCoin neuromodulation device will be 
implanted s ubcutaneous ly in the right or left leg of patients with urgency urinary 
incontinence.  After a [ADDRESS_908014] their devices 
activated ( turned ON).  After 3 months  of device therapy ( occurring [ADDRESS_908015]-
implant), the primary endpoint will be assessed.  It is anticipated that subjects will reach 
the full therapeutic effect at approximately 3 months  of the rapy.  Subjects will be 
followed for an additional 9 months  to assess the safety of maintenance stimulation 
therapy with fewer sessions occurring during th is time interval . 
30. American Urological Association, OVERACTIVE BLADDER DIAGNOSIS AND 
TREATMENT OF OVER ACTIVE BLADDER IN ADULTS AUASUFU Guideline 
(2012); Amended (2014).  
 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-[ADDRESS_908016] provided 
informed consent, will be enrolled . It is estimated that approximately 100 subjects will be 
enrolled into baseline evaluation in order to yield 50 implanted  subjects  (where up to 35 
subjects in the [LOCATION_002] will be implant ed). 
All eligible enrolled subjects are implanted with the eCoin system  after baseline 
assessment .  The implantation side will be left to the discretion of the investigator. 
Approximately [ADDRESS_908017]’s comfort.   
3-3-2-[ADDRESS_908018] 6 months  (self-reported) .  
3. Individual has at least one urgency incontinence epi[INVESTIGATOR_1865], on average over a 
one-day period, as determined over a 3 -day period.  
4. Individual is unre sponsive to , inadequately responsive to, or intolerant of 
behavioral, rehab ilitation , and  pharmacologic therapy .  
5. Individual is able to give his or her written, informed consent.  
6. Individual is mentally competent and able to understand all study requirements.  
7. Individual is willing and able to complete a 3 -day voiding diary and quality of life 
questionnaire.  
8. Individual is without  pharmacological treatment of overactive bladder  
(antimuscarinics  and beta -3 agonists)  for [ADDRESS_908019] void residual (i.e., greater than 150 cc).  
5. Individual has  clinically significant urethral stricture  disease  or bladder neck 
contracture . 
6. Individual has an active urinary tract infection at time of enrollment.  
7. Individual has recurrent urinary tract infections defined as 4 or more UTI’s  per 
year.  
8. Individual has peripheral arterial disease.  
9. Individual has chronic venous insufficiency with a history of skin change 
(hyperpi[INVESTIGATOR_371], lipodermatosclerosis, ulceration) in the ankle region.  
10. Individual has morbid obesity.  
11. Individual has had positive urine cytology or diagnosis of bladder or prostate 
cancer.  
12. Individual has  neurogenic bladder  dysfunction . 
13. Individual is taking an alpha -blocker for benign prostatic hyperplasia.  
14. Individual  is pregnant or intends to become pregnan t during the study.  
15. Patient is b reast feeding or is less than [ADDRESS_908020] -partum.  
16. Individual has the presence of urinary fistula, bladder stone,  or interstitial cystitis . 
17. Individual has uncontrolled diabetes mellitus.  
18. Individual has  an implanted device . 
19. Individual has been previously treated with sacral nerve stimulation.  
20. Individual has  been treated with onabotulinum toxin A in the previous 9 months 
prior to enrollment . 
21. Individual has been treated with percutaneous tibial nerve s timulation within the 
previ ous 12  weeks prior to enrollment .  
22. Individual is aware that he or she will need an MRI scan during the study period.  
23. Individu al has a clotting or bleeding disorder; antiplatelet and anticoagulant 
therapy may be continued or held at the discretion of the investigator .  
24. Individual has a clinically significant peripheral neuropathy.  
25. Individual is n eutropenic or immunocompromised . 
26. Individual has had previous surgery and/or significant scarring at the implant 
location.  
27. Individual has ongoing dermatologic cond ition at the implant site, including but 
not limited to dermatitis and autoimmune disorders.  
3-3-[ADDRESS_908021] of this treatment modality on their incontinence  with 
minimal risk.  However, the following are considerations:  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 26 of 83  Some subjects may not receive c linical benefit from eCoin therapy , but are to 
continue with follow -ups until study completion.  Note that in some cases, benefit 
may be identified over time based on late response and c umulative effects of 
treatment.  
 Subjects are intended to be without  pharmacological medications for overactive 
bladder .  If the addition of  medications  is medically necessary  as described 
herein,  such changes may affect a subject’s continued participation in the study.  
 Study Procedures  
All subjects  will be followed for [ADDRESS_908022]-activation : collecting a 3-day voiding diary 
reporting the number of incontinence epi[INVESTIGATOR_1841], number of micturitions, voided volumes, 
and quality of life  scores at 1, 2, 3, [ADDRESS_908023] patients 
that appear to qualify from medical records.   Investigators will also seek referrals from 
other urology, urogynecology, and gynecology practices .  A member of the  site’s clinical 
research team shall assess whether the individual seems suitable for the study.  The 
patient should have a medical history of overactive bladder with urge ncy incontinence .   
Patients with urgency incontinence  who appear to meet the inclusi on/exclusion criteria 
from medical records will be contact[CONTACT_672012], including:  
 
 reason for being identified ( refractory urgency urinar y incontinence ) 
 therapy description  
 potential benefits  
 risks 
 compensation  (see 3-12-5)  
 
If the patient is interested thereafter, they will be brought into the research clinic  for 
further screening and informed consent.   
 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 27 of 83 3-4-2 Visit Overview  
The ordered enrollment process consists of screening including obtaining written 
consent, completing the baseline evaluation , implantation of eCoin system , and 
establishing the stimulation paradigm for  the patient. A flowchart depi[INVESTIGATOR_671991] 1.  The timing of visits 1 through 4 is described in relationship to the 
immediately previous visit, while the timing of visits 6 through 10 is described in 
relationship to visit 5 (the activation).  
 
For visits involving a [ADDRESS_908024] 3 days prior to  each follow up visit.   
 Visit 1: Screening Procedures (informed consent , urinalysis, PVR, history and 
physical examination, subjects begin 2 week wash -off of OAB medications if 
applicable, concomitant medication therapy review, eligibility determination)  
 Visit 2: Baseline  Assessments ([ADDRESS_908025] sent home 
with 7 -day TENS trial instructions ) (Time: Between 0 and 28 days from Visit 1)  
 Visit 3: Implant Procedure  (Time: Between 0 and 14 days from Visit 2)  
 Visit 4: Incision Healing Check (week 2) (Time: Between 9 and 19 days from Visit 
3) 
 Visit 5: Activation (week 4) (Time: Between 23 and 33 days from Visit 3)  
 Visit 6  ([ADDRESS_908026] -activation): Follow up Assessments (3 -day voiding diary, 
adverse event assessment, concomitant medicati on therapy review, patient 
surveys including I -QoL, patient satisfaction, and patient global assessment of 
improvement) (Time: Between 23 and 33 days from Visit 5)  
 Visit 7  ([ADDRESS_908027] -activation): Follow up Assessments (3 -day voiding diary, 
adverse event assessment, concomitant medication therapy review, patient 
surveys including I -QoL, patient satisfaction, and patient global assessment of 
improvement) (Time: Between 51 and 61 days from Visit 5)  
 Visit 8 ([ADDRESS_908028] -activation): Follow up Assessme nts (3 -day voiding diary, 
adverse event assessment, concomitant medication therapy review, patient 
surveys including I -QoL, patient satisfaction, and patient global assessment of 
improvement) (Time: Between 79 and 89 days from Visit 5)  
 Visit 9 ([ADDRESS_908029]-activation): Follow up Assessments (3 -day voiding diary, 
adverse event assessment, concomitant medication therapy review, patient 
surveys including I -QoL, patient satisfaction, and patient global assessment of 
improvement) (Time: Between 107 and 117 day s from Visit 5)  
 Visit 10 ([ADDRESS_908030] -activation): Follow up Assessments (3 -day voiding diary, 
adverse event assessment, concomitant medication therapy review, patient 
surveys including I -QoL, patient satisfaction, and patient global assessment of 
improv ement) (Time: Between 1 63 and 1 73 days from Visit 5)  
 Visit 11 ([ADDRESS_908031] -activation): Follow up Assessments (3 -day voiding diary, 
adverse event assessment, concomitant medication therapy review, patient 
surveys including I -QoL, patient satisfaction, a nd patient global assessment of 
improvement) (Time: Between 331 and 341 days from Visit 5)  
 Visit 12 ([ADDRESS_908032] -activation): Explantation to follow Visit 11 (Time: On or 
within 30 days of Visit 11)  
 Visit 13 Incision Healing check ([ADDRESS_908033] -explanta tion): visit to assess 
wound healing. (Time: Between [ADDRESS_908034] -explantation).  
 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 28 of 83  
 
Screening  
Baseline  
Implantation  
Incision Healing Check  
Activation  (Follow up Clock Starts)  
1 Month Follow -up 
2 Month Follow -Up 
3 Month Follow -Up: Primary Endpoint  
4 Month Follow -Up 
6 Month Follow -up 
12 Month Monitoring  
Incision Healing Check  
Demographics, screening exam, 
physical exam, & medical history  X            
Eligibility Determination  X X           
Informed Consent  X            
3-day Voiding Diary Reminder  
Call X X X    X X X X X  
3-day Voiding Diary  X X X    X X X X X  
Post Void Residual (PVR)  X            
Urinalysis   X           
I-QoL Assessment   X     X X X X X  
7-day TENS Trial Data Collection    X          
Patient Reported Satisfaction  
Assessment        X X X X X  
Patient Global Impression of 
Improvement        X X X X X  
Implant or Explant Procedure    X        X  
Incision Assessment     X        X 
Activation      X        
Completion of Primary Endpoints         X     
Completion of Study             X 
Subject Assessment for AEs    X X X X X X X X X X 
 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 29 of 83      
 

 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 30 of 83 Figure 3-1: Summary of Study Process  
3-4-3 Screening f or Eligibility Procedures  
Interested adults who are known or present at the research site with refractory urgency 
urinary incontinence  may be initially screened for inclusion in the study. Patients’ 
medical records will be reviewed for inclusion/exclusion criteria.  
Patients who initially qualify will be scheduled for a screening visit to assess general 
health and overactive bladder cond ition.  Urinalysis will be utilized  after providing their 
informed consent .  Patients will also be questioned for inclusion/exclusion criteria in 
addition to medical record review.  A history will be taken, physical exam will be 
performed, and g eneral heal th to participate in the study will  be further evaluated by [CONTACT_672013].   
3-4-[ADDRESS_908035] urination.  
3-4-5 Informed Consent Procedures  
The study as contained in the Informed Consent (see Att achment 4-5) will be presented 
to the individual for consideration at the screening visit. The individual will be given 
adequate time to have all questions answere d and to carefully consider participation. If, 
after understanding the purpose, potential risk s, potential benefits, and requirements of 
the study, as well as his or her rights as a research participant, the individual agrees to 
participate as evidenced by  [CONTACT_11682], the subject will be 
enrolled to enter the baseline period.  The subject should be allowed to take informed 
consent documents home for further consideration, if needed, and scheduled with an 
additional visit to complete the screening visit.  Informed Consent shall be included in the 
patient’s medical record file and noted in the screening CRF.  
3-4-[ADDRESS_908036] provided informed 
consent  will be  asked to come back for baseline assessments.  
Baseline assessments will include : 
1) 3-day voiding diary;  
2) I-QoL assessment ; 
3) TENS trial instructions;  
Study staff will schedule subject’s implantation procedure to follow baseline  
assessments.  
 
 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 31 of 83 3-4-7 TENS Trial  
At baseline, subjects will be sent home with a TENS (transcutaneous electrical nerve 
stimulation) unit and instructions to perform TENS of the tibial nerve twice daily for seven 
days.  The electrical paradigm will be preset to match the electrical paradigm  of eCoin 
(pulse width of 0.2 ms and frequency of 20 Hz), but the subject will set the amplitude of 
stimulation to the upper level of comfort.  Subjects should perform one thirty minute 
session in the morning and one in the evening for 7 days (total of 14 sessions).  Subjects 
will also be asked to complete a voiding diary in the last three days of the TENS trial.  
This TENS trial will occur after the baseline visit but before the implantation visit.  The 
purpose of this trial is to ascertain whether there i s a relationship between responders to 
TENS and responders to eCoin therapy.  Patients will not be excluded from participation 
in this study based on response to TENS.  This procedure is optional in New Zealand.  
3-4-[ADDRESS_908037] will be provided with a 3 -day voiding diary to complete in the 7 days prior to 
the next visit s (occurring 1, 2, 3, [ADDRESS_908038]-activation ). Subjects will be 
reminded by [CONTACT_32216] a member of the study staff at least [ADDRESS_908039]’s upper level of comfort . Subjects will be informed that they may 
periodically feel a tingling or notice a muscle twitch ; but if they do , it would be transient 
and they should not feel anything most of the time, if at all .  In particular, subjects may 
feel a motor response (flexing of the big toe and/or fanning of the other toes) and 
sensory response (a radiating sensation is felt at the sole  of the foot and in the toes).   
 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-[ADDRESS_908040] activation , with the 
primary analysis at 3 months . 
1) Overactive bladder  medications  and doses should  not be given through the 3 
month  primary endpoint  (unless medication  is medically necessary according to 
the “Escape Treatment” guidelines below). 
2) At least [ADDRESS_908041] will be responsible to  
complete a 3 -day voiding diary to be brought with them to each appointment.  
3) Assessments at these follow -up visits are described in the Visit Overview Section 
3-4-2. 
At the follow -up visit [ADDRESS_908042] activation , unless judged medically necessary.  Agents added or 
withdrawn are at the discretion of the Investigator and managing physician(s) . Any such 
adjustments  are to be noted on the CRF for the next Follow Up visit .  
 Study Endpoints  
3-5-[ADDRESS_908043] -activation .  
3-5-2 Key Second ary Outcome Measure  
The percentage of responders in subjects implanted with the device.   Responders are 
defined as subjects with a 50% or greater reduction in urge incontinence epi[INVESTIGATOR_671992] -activation.   
3-5-[ADDRESS_908044] -activation.  
The proportion of subjects who had a 100% reduction (dryness) in the # of incontinent 
epi[INVESTIGATOR_1841]/[ADDRESS_908045] of other chronic medical conditions like osteoarthritis,  chronic obstructive 
pulmonary disease, and stroke  (31).  Percutaneous tibial nerve stimulation achieves a 
50-70% response rate.  Thus, it is anticipated that not a ll subjects will respond to eCoin 
therapy, but that a high level of response in responders would translate to a meaningful 
contribution to overactive bladder care.  Thus, the primary outcome focuses on a 
relatively objective and significant symptom of over active bladder, the number of 
incontinence epi[INVESTIGATOR_11630] a 3-day period in responder subjects.  Of the secondary 
outcomes, quality of life is an important measure of the overactive bladder condition 
because overactive bladder is a symptom -based diagnosis.  Th e degree of bother 
caused by [CONTACT_11684], treatment intensity, and satisfaction 
with treatment.  However, there has been a historical lack of standardization of such 
patient reported questionnaires on the quality of life of incon tinence patients.  Thus, 
Valencia selected two questionnaires  based on evidence that each, the I -QOL and the 
ICIQ-UI, proved to be valid and reproducible as a self -administered measure for 
assessing quality of life in  patients with urinary incontinence ( 32, 33).   
 
Given the expected therapeutic equivalence of percutaneous nerve stimulation of the 
tibial nerve  to eCoin stimulation of the tibial nerve, it is not expected that the therapy will 
cause adverse events.  Fur thermore, prior experience with eCoin implantation in the 
forearm for the treatment of hypertension, shows th at the primary concern was infection 
or symptoms of infection, which tend to appear by [ADDRESS_908046] of chronic conditions.  Health Rep.  2003;14:41 –53. 
32. Wagner, T. H., et al. "Quality of life of persons with urinary incontinence: 
development of a new measure."  Urology  47.1 (1996): 67 -71. 
33. Hajebrahimi, Sakineh, et al. "Validity and reliability of the International 
Consultation on Incontinence Questionnaire -Urinary Incontinence Short Form 
and its correlation with urodynamic findings."  Urology journal  9.4 (2012): 685.  
 
 Risk Analysis  
3-7-1 Overview  
The eCoin system risk assessment (Attachm ent 4-14) has been completed per  FDA-
recognized Consensus  Standard 5 -40: ISO [ZIP_CODE]. The risk analysis method identifies 
each potential hazard which could result in patient harm, with action taken  to reduce risk 
when the risk estimation for any potential hazard exceeds an acceptable level. The risk 
analysis for the eCoin system and the control ler was performed early in the design 
process and has been updated throughout the process. The identified, anticipated risks 
were mitigated so that all potential hazards were reduced to a n acceptable  severity and 
occurrence .   
To verify mitigation of risk,  the eCoin system  has undergone testing for safety, essential 
performance, design verification and marking per applicable parts of IEC [ZIP_CODE] -
1:2005+A1:2012(E) and ISO [ZIP_CODE] -1:[ZIP_CODE](E) as well as biocompatibility testing to be 
compliant with all applicable ISO [ADDRESS_908047] in human feasibility trial from 2013 
through 2016 for the treatment of drug resistant hypertension in adults.  The system 
parameters were 2 pul ses per second at a pulse width of 0.5 ms with amplitudes ranging 
from 0.5 mA to 25 mA.  There were no stimulation therapy related adverse events during 
this study. Section 2-2-2-1 is a summary of the safety results .  In this proposed study, 
the eCoin system parameters will be 20 pulses per second at a pulse width of 0.2 ms 
with amplitudes ranging from 0.5 mA to 15 mA.  The proposed system parameters 
match that utilized by [CONTACT_672014] ( 3, 13, 17) and the same parameters 
used  by [CONTACT_672015] (K132561) that also stimulate the tibial nerve for treatment 
of ove ractive bladder.   According to the American Urological Association’s guideline on 
the diagnosis and treatment of overactive bladder  (34), percutaneous tibial nerve  
stimulation carried minor adverse events in reviewed studies.  The most frequently 
reported events were painful sensation during stimulation that did not interfere with 
treatment and minor bleeding at the insertion site.  In the panel’s view, benefits out weigh 
risks/burdens for the use of percutaneous tibial nerve stimulation in the thoughtfully -
selected and counseled patient who is highly motivated to make the office visits required 
for repeated percutaneous administration of tibial nerve stimulation.  
34. Gormley  A, Lightner  D, Burgio  K, Chai  T, Clemens  JQ, Culkin  D, Das  A, Foster  
HE, Scarpero  HM, Tessier  C, Vasavada  SP, Diagnosis and Treatment of 
Overactive Bladder (Non -neurogenic) in Adults: AUA/SUFU Gui deline.  American 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 35 of 83 Urological Association Education and Research  
https://www.auanet.org/education/guidelines/overactive -bladder.cfm  
3-7-[ADDRESS_908048] a clinically and statistically significant lower quality 
of life, lower depression status, and poorer quality of sleep ( 35).  Overactive bla dder also 
causes additional health  problems including increased risk of falls and fractures 
(presumably from nocturia in the elderly), urinary tract and skin infections, sleep 
disturbances and depression (36).  Most studies about the cost of overactive bladder 
focus on the economic burden of overactive bladder, showing a total cost to the US 
healthcare system of $26.3B a year (37).  Patients with r efractory  urgency urinary 
incontinence  are those  who are not achieving adequate control of incontinence 
symptoms through available modes of therapy.  Such modes include behavioral therapy , 
pelvic floor exercises, and pharmacological therapy.  
35. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P,Herzog AR, Corey R, Hunt 
TL and Wein AJ, Prevalence and burden of overactive bladder in the United 
States  (NOBLE Study) , World J Urol (2003) 20: 327 –336. 
36. Brown  JS, McGhan  WF, and Chokroverty  S, Comorbidities Associated With 
Overactive Bladder , The American  Journal  of Managed  Care, Vol. 6, N o. 11, 
SUP (2000), S574 -S579.  
37. Wagner TH, Hu TW. Economic costs of  urinary incontinence in 1995. Urology  
1998;51:355 -361. 
3-7-3 Justification for Investigation  
3-7-3-1 Potential Benefits of Treatment  
According to the American Urological Association and its guideline for diagnosis and 
treatment of overactive bladder, the Panel interpreted the available percutaneous tibial 
nerve stimulati on data to indicate that percutaneous tibial nerve stimulation can benefit 
a carefully selected group of patients characterized by [CONTACT_672016] .  The Grade C evidence supports a 
potential benefit of tibial nerve stimulation in overactive bladder patients of 
improvements to incontinence epi[INVESTIGATOR_1841], voiding volume, quality of life, frequency, and 
nocturia.  Furthermore, i n a study by [CONTACT_11688] -Agro et al., patients matching the 
population for the proposed study —females with detrusor overactivity  incontinence —
showed statistically and clinically significant improvements in mean incontinence 
epi[INVESTIGATOR_11629] 3 days, mean voids per day, mean voided volume, and mean QoL score 
(17).  Thus, potential benefits of tibial nerve stimulation by [CONTACT_672017][INVESTIGATOR_1841], voiding volume, frequency, and quality of life.    
3-7-4 Additional Safety Profile Information  
3-7-4-1 Description of Procedure  
eCoin is placed into a subcutaneous pocket in the lower leg . The anatomical structures 
involved in the implantation procedure are skin, subcutaneous tissue and fascia. The 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 36 of 83 eCoin sits above the fascia so  the deeper stru ctures are not affected. Within the 
subcutaneous pocket, there are no significant nerves or vessels, other than 
subcutaneous veins which are of minimal signif icance.  eCoin is placed about 3  mm 
above its target nerve ( tibial nerve).  
Similar to other inert prosthetic devices, a fibrous capsule is expected to form around the 
eCoin system. This capsule stabilizes the implant at its desired location and 
compartmentalizes it from the surrounding tissues (skin, subcutaneous fat and fascia).  
3-7-4-2 Therapeutic or Stimula tion Risks  
Although stimulation could briefly exceed a comfortable level  during the activation 
procedure , no serious complications from tibial nerve stimulation are known or 
anticipated.  Stimulation pulses are charge balanced and at a charge density level  
known to be safe for neuromodulation with platinum electrodes ( ≤ 100 C/cm2). If 
stimulation intensity above the subject’s comfort level is reached during programming  in 
the clinic , the subj ect may feel discomfort or pain  until the stimulation level is tu rned 
down.  The subject may also experience a muscle twitch related to stimulation of the 
tibial nerve.  Discomfort or muscle twitch is managed through optimal setting of 
stimulation amplitude  to subject comfort levels. Adjustments to stimulation levels ar e 
only made in the clinic where the patient response can be monitored and adjustments 
made as needed.  
Furthermore, the energy discharge of the eCoin  battery  is such that no harm will arise  
from heating due to a battery short. Direct shorting of the 120 mWh battery delivers less 
than 200 mW or 20 mW/cm2 of heat from the device surface to tissue . This ensures a 
safe level of tissue heating (less than 2 degrees Centigrade) in a worst case direct short 
failure condition . 
3-7-4-[ADDRESS_908049] probable risks associated with eCoin implantation include ecchymosis, 
erythema, and incisional pain at the implant site, intermittent paresthesias of the toes, 
foot, or lower leg , and other wound healing complications. Other risks are categorized as 
uncommon or rare and are reported below:  
UNCOMMON (<5%)  
• Hematoma at the incision site  
• Implant site infection that leads to device explant  
• Persistent implant site pain  
• Severe pain during or shortly after the procedure  
• Persistent wound healing comp lications lasting beyond [ADDRESS_908050] implant  
• Persistent stimulation discomfort  
RARE (<1%)  
• Wound dehiscence  
• Allergic reactions to local anesthesia  
• Inflammation of nearby [CONTACT_11690]  
• Localized neuritis  
• Surgical injury to adjacent nerves, vessels o r tendons  
• Allergic reaction to implanted materials  
• Implant device failure leading to explant  
• Implant device extrusion  
• Implant device migration requiring explant or revision  
• Implant device inversion  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 37 of 83 Device -related risks of the eCoin system can be  deduced from the 50 year field of 
neuromodulation.  The primary risks of importance are infection and lead -related 
problems (e.g. leadwire break, leadwire migration).   For the leadless eCoin system, lead -
related problems are not relevant.  The rate of inf ection can be reasonably estimated 
based upon other neuromodulation devices, an implantable device whose implantation 
site is nearby [CONTACT_672018], and the OUS clinical study.  Infection can be mitigated 
throu gh surgical training, adequate manufacturing co ntrols , and adequate after -care 
instructions .  Infection can be resolved through explantation of eCoin and/or antibiotics.  
If needed, explantation of the eCoin device can be performed easily  through simple 
opening of the capsule and removal of the device . If the capsule itself has  a significant 
problem such as deep infection or dense scar tissue causing significant discomfort, then 
the capsule might require surgical excision, a procedure known as capsulectomy.  
In the OUS clinical study of eCoin, the rate of  patient infections requiring explantation 
was approximately 4.2%. See 2-2-2-1 for details.  
The eCoin utilizes established biocompatible materials and manufacturing processes 
that are typi[INVESTIGATOR_11632] ( titanium hermetic enclosure, silicone 
elastomer insulation coating (MED -4870) and with platinum stimulating electrodes ). 
3-7-[ADDRESS_908051] em has been developed under design control in accordance with QSR 21 
820.30 and ISO [ZIP_CODE] . 
3-7-5-1 Risk Management  
Risk management conforms to ISO [ZIP_CODE]:2012(E) . A Risk Assessment has been 
completed for the SNS system based on Use , Design and Process FMEAs (See Ri sk 
Assessment Report 110 -1493 in attachment 4-14). 
3-7-5-[ADDRESS_908052]  been completed 
per applicable parts of IEC [ZIP_CODE] -1:2005+A1:2012(E) in compliance with active 
implantable medical devices ISO [ZIP_CODE] -1:2000(E)  and software life cycles per IEC 
[ZIP_CODE]:[ADDRESS_908053] duration 
(>30 days).  The eCoin system  has been subject to biocompatibility testing in 
accordance with the ISO [ADDRESS_908054]  Title Result  
ISO [ZIP_CODE] -3:200 3 Biological evaluation of medical devices - Part 3: 
Tests for genotoxicity, carcinogenicity and 
reproductive toxicity.   
ISO Bacterial Mutagenicity Test – Ames Assay  
Mouse Lymphoma Assay  Pass   
Pass  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-[ADDRESS_908055]  Title Result  
ISO [ZIP_CODE] -5:2009  Biological evaluation of medical devices - Part 5: 
Tests for in vitro cytotoxicity.  
Cytotoxicity – Elution Test - MEM Extract   Pass  
ISO [ZIP_CODE] -6:[ADDRESS_908056]  – 90 day s 
Systemic Toxicity Study of “SNS Biocompatibility 
Test Device” in Sprague Dawley Rats following 
Subcutaneous Implantation for 90 Days  Pass  
Pass  
ISO [ZIP_CODE] -7:2008  
/AC:2009  Biological evaluation of medical devices -- Part 7: 
Ethylene oxide sterilization residuals.  Pass  
ISO [ZIP_CODE] -10:2010  Biological evaluation of medical devices - Part 10: 
Tests for irritation and delayed -type hypersensitivity.  
Intracutaneous (Intradermal) Reactivity Test in New 
Zealand White Rabbits  
Maximization Test for Delayed -Type Hypersensitivity 
in Hartley Guinea Pi[INVESTIGATOR_622229] [ZIP_CODE] -11:200 6 Biological evaluation of medical devices - Part 11: 
Tests for systemic toxicity  
Acute Systemic Toxicity Test in CD -[ADDRESS_908057] in New Zealand White Rabbits  Pass  
Pass  
Table 3-2:  ISO [ZIP_CODE] Biocompatibility Testing  
3-7-5-4 Sterilization and Sterile Packaging  
The ethylene oxide sterilization process for the eCoin device was been developed , 
validated  and is controlled per ISO [ZIP_CODE]:2007  (see attachment 4-17). The sterile 
package sealing process and shelf life were  developed and validated per ISO [ZIP_CODE] 
(see attachment  4-18). 
 Description of the Device  
Valencia Technologies eCoin therapy for refractory urinary urge incontinence  provides 
electrical stimulation to the tibial nerve from a small self -contained implant placed in the 
subcutaneous space over the tibial nerve in the lower leg .  Subjects receive the implant 
unilaterally in a simple pro cedure under local anesthetic.  
To stimulate the tibial nerve with the eCoin implant, the same parameters as previously 
demonstrated in animal and human studies are app lied.  The stimulation rate is 20  
pulses per seco nd (pps) at a pulse width of 0.[ADDRESS_908058] with an external controller. After 
activation, the implant automatically provides 30 minute stimulation sessions according 
to a fixed treatment interval schedule.  In between sessions, the amplitude can be 
adjusted or au tomatic therapy can be turned off.  The device contains a battery that will 
typi[INVESTIGATOR_11634] 3 to 5 years before the device requires replacement.    
3-8-1 Components  
1) eCoin  Implant – The implant is a coin-sized leadless battery powered device [ADDRESS_908059] with tissue are the platinum 
electrodes , and the silicone elastomer jacket  (NuSil MED 4870) that covers the  
titanium housing.  Each  implant receives a unique traceable serial number including 
labeling to place in recipi[INVESTIGATOR_285183].  
 
2) External Controller – The external controller programs the device via a magnetic field 
using a custom access code secured wireless protocol . 
 
3-8-2 Stimulation Settings/Parameters  
Amplitude Range: 0. 5 up to 15 mA (programmable)  
Rate: 2 0 pulses per second (fixed)  
Pulse Width: 0.2  ms (fixed)  
Treatment Duration: 30 Minutes (fixed)  
Treatment Interval: [ADDRESS_908060] 12 weeks (42 sessions) and every 15 days  
thereafter (fixed)   
3-8-[ADDRESS_908061]’s upper most comfortable level.  Once activated, 
the eCoin  applies  a [ADDRESS_908062] Compliance Monitoring  
eCoin  Therapy:   Neuromodulation therapy is provided automatically by [CONTACT_622245].   
Drug Therapy:  Subjects will be asked whether they are taking an overactive bladder 
medication through the primary endpoint to confirm that subject s are overactive bladder 
medication free .   
Data:   Compliance with voiding diaries  is established  through review by [CONTACT_11692].   
Appointment Compliance :  Clinics ’ designated study coordinators  will ensure subjects 
are compliant with  study  appointmen ts within the scheduling parameters outlined in the 
Visit Overview described in Section [ADDRESS_908063] and subjects  will be medically monitored by [CONTACT_58404] s. 
3-8-6-2 Definitions of Adverse Events  
Adverse Event  (AE): Any untoward medical occurrence in a study participant whether 
or not there may be a causal relationship with this t reatment / intervention.   This can 

 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 41 of 83 include (but is not limited to) worsening of subject ’s overactive bladder  condition and/or 
occur rence of serious sudden events . 
 
System and Procedure Related Adverse  Event : Any device or placement procedure 
related adverse event.  This can include risks associated with the procedure , implant site  
or sti mulation such as infection, or unexpected related adverse event s that occur in 
relation to  implant  placement,  median nerve sti mulation  or device failure .  The Sponsor 
maintains a list of expected adverse events and is responsible for determining 
expected ness .  
3-8-6-3 Classification  of Events  
 Relationship  
YES- related :  The event has a  reasonable possibility of a causal relationship t o the 
administration of tibial nerve stimulation (procedure , device or stimulation) and no other 
etiology explains the event.  
 
NO- not related : The event is independent of tibial nerve s timulation (procedure , device  
or stimulation ) and/or the event appe ars to be explained by [CONTACT_11693].  
 Severity  
Mild: Transient or mild discomfort (<48 hours); no medical intervention/therapy required 
and do es not interfere with the subject ’s daily activities . 
Moderate : Some limitation in activity; some assistance may be needed; no or minimal 
medical intervention/therapy required.  
Severe : Marked limitation in activity;  interrupts participant’s usual daily activity and may 
requi re medical intervention/therapy;  hospi[INVESTIGATOR_9841] . 
Serious :  Results in death  during the study period ; is life -threatening ; requires 
hospi[INVESTIGATOR_1081] ; results in persistent or 
significant disability or incapacity ; results in a congenital anomaly or birth defect ; 
requires medical or surgical intervention to preclude permanent impairment of a body 
function or to prevent permanent damage to a body structure, where  the device is 
suspected to cause such intervention; other important medical events not captured by 
[CONTACT_672019].  
 Expected ness  
Expected : Any adverse reaction whose nature and intensity are consistent with that 
described  under risk assessment.  
 
Unexpect ed: Any adverse reaction not included under risk assessment.  
3-8-6-[ADDRESS_908064]  
(DSMB) with regards to:  
1) Relatedness or causality to the study device  
2) Severity  
3) Expected ness  
4) Action taken  
The Sponsor is responsible for determining if an adverse event is unexpected.  If 
expec tedness is assessed by a medical reviewer as unexpected, the Sponsor will be 
notified and will evaluate and assign a final determination  that may or may not result in 
reporting requir ements.  
 
At each contact [CONTACT_1155], the Investigator will obtain information on AEs by 
[CONTACT_11695].   In the CRF for visits, if an event is reported, the 
AE checkbox will be selected.  This selection will trigger a separate form to b e filled out 
which records the following information:  
1. Subject Number  
2. Adverse Event (AE)  
3. Date of AE onset  
4. Date of AE cessation  
5. Severity  
6. Expectedness  
7. Causality  
8. Was the patient hospi[INVESTIGATOR_057]?  If yes, provide dates.  
9. Will the patient continue with treatment, and will any be missed?  
10. Did the patient add or change any other associated medication and what 
were the changes/additions?  
11. Was there any other action taken?  
When an AE has been recorded, the PI [INVESTIGATOR_11637] -PI [INVESTIGATOR_671993] .  The Study monitor will keep track of the 
reported AEs.  A sample of the AE report  form is  in Attachment 4-9. 
3-8-6-5 Reporting Procedures  
For Serious  Adverse Events ( SAEs ) or suspected Unanticipated Adverse Device Effects 
(UADEs ), the Study Coordinator, the PI [INVESTIGATOR_671994].  The timeline for 
medical review and assessment is [ADDRESS_908065] -study adve rse events should be 
reported to the Sponsor after the study period if they are:  
1) AEs that are device related resulting in  a reprogramming, revision surgery or 
explant ( explant for r easons other than  for normal end of life – e.g. battery 
depletion) for which the patient presents to the PI.  
2) AEs that occur  during or related to an explant procedure performed at the normal 
device end of life.   
3-8-[ADDRESS_908066] Withdrawal & Termination  
3-8-7-[ADDRESS_908067]’s continued participation in the study must be terminated for the following 
reasons:  
1) In the Investigator ’s opi[INVESTIGATOR_1649], continued participation would be de trimental to the 
subject’s well -being.  
2) Subject is noncompliant with the protocol . 
3) Subject is lost to follow up (after [ADDRESS_908068]).  
4) Subject becomes pregnant during the trial.  
5) Subject uses prohibited treatments, medication changes, or proce dures as 
defined in the exclusion criteria.  
The subject ’s eCoin system  must be recommended to be explanted if subject 
participation is  terminated.  
3-8-7-3 Withdrawal/Termination Procedures  
If premature withdrawal occurs for any reason, the Investigator  must make e very effort to 
determine the primary reason for a subject’s premature withdrawal from the study and 
record this information on the C ase Report Form for reporting to the Sponsor.  
Subjects enrolled in the study will not be repla ced if they withdraw  or are t erminated from 
the study  after device activation .  Provisions  for device explantation will be arranged.  
3-8-7-[ADDRESS_908069].  The 
Investigator  may be informed of additional procedures to be followed in order to ensure 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 44 of 83 that adequate consideration is given to the protection of the subjects’ interests.  The 
Investigator  will be responsible for informing the IRB of the early termination o f the trial.  
If req uired, provisions for the explant  of the eCoin system will be arranged.  
3-8-7-[ADDRESS_908070] implantation (a 
primary safety endpoint)  and [ADDRESS_908071] activation  (primary  safety and efficacy  
endpoint).  This DSMB will meet telephonically at least monthly  until the study reaches 
the primary endpoint to review aggregate and individual subject data related to safety, 
data integrity and overall conduct of the trial.  They will be responsible for the review of 
safety endpoints .  The DSMB will provide recommendations to continue or terminate the 
trial depending upon this review .  A DSMB charter is set forth in a DSMB C harter 
document  (see 4-10).  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 45 of 83 
 Data Analysis Plan  
3-9-1 Data Collection  
All study data will be recorded onto Case Report Forms (CRFs) provided by [CONTACT_11696] . All CR Fs will be compl eted using  de-identified data. 
CRF compl etion may be delegated to other study personn el but the Investigator 
remains responsible  for the accuracy and integrity of all data entered on CRFs. CRFs 
will be compl eted and sent to the designated representative for Valencia 
Technologies as directed, in an expedited fashion.  All CRFs will be completed by  
[CONTACT_11698]. Valencia or its designee  will work with participating sites to 
secure data clarification and to obtain addition al relevant medical documentation on 
participants enrolled into this t rial.   
CRF’s for the study include:  
1) Screening  
2) Baseline  
3) Implant ation  
4) Implant Healing Check  
5) eCoin Activation   
6) Safety Follow Up ([ADDRESS_908072] -activation)  
7) Follow Up ( 2, 3, [ADDRESS_908073]-activation ) and long  term monitoring ([ADDRESS_908074] -activation)  
8) Adverse Event  
9) Study Termination  
3-9-[ADDRESS_908075] source 
documentation in accordance with the Clinical Monitoring Plan in Attachment 4.22 . 
Moni tors will confirm that written Informed Cons ent was properly obt ained prior to 
enrollment of all participants. Any evident pattern of non-compliance will be 
addressed with the Investigator. If appropriate corrective actions  are not subs equently 
undertaken, Valencia  reserves the right to susp end enrollment at the site and/or 
withdraw the site from the study. 
At the close of the study at a research site, the clinical monitor will make a final on-
site visit.  The purpose  of this visit is to collect all outstanding  study data documents, 
ensure that the Investigator 's files are accurate and complete, review record retention 
requirements with the Investigator , make a final accounti ng of all study supplies  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-[ADDRESS_908076]-activation.  
Key Secondary Endpoints   
The key secondary endpoint is the percentage of responders in subjects implanted with 
the device.   Responders are defined as subjects with a 50% or greater reduction in urge 
incontinence epi[INVESTIGATOR_671995] -activation.   
3-9-3-[ADDRESS_908077]  (reduction in leakage epi[INVESTIGATOR_1841])  in 
responder subjects after three months of eCoin therapy . The null hypothesis is that  
there i s no reduction in the mean number of leakage epi[INVESTIGATOR_671996] 3 
months of therapy .   
The primary effectiveness hypotheses being tested is: 
H0: µ(Subject ) ≤  µ(Subject Baseline )  vs. H1: µ(Subject ) > µ(Subject Baseline ) 
Where µ(Subject ) and  µ( Subject Baseline ) are the mean number of leakage epi[INVESTIGATOR_671997] -activation  and at baseline . Rejection of the null hypothesis at a 
two-sided significance level of 0.[ADDRESS_908078] -activation.  The response variable  is the change 
from baseline in the number of urge incontinent epi[INVESTIGATOR_11645] 3 months of therapy 
([ADDRESS_908079] -activation ).  For the primary endpoint, urge incontinent  epi[INVESTIGATOR_671998]  3-day voiding  diaries administered  at baseline  and [ADDRESS_908080] three urge 
incontinence epi[INVESTIGATOR_17767] 24 hours on a three -day voiding  diary  at baseline .  A 
sample size of 25 subjects  provides  80% power to detect  a true difference  of 0.[ADDRESS_908081] deviation in the in the response variable is 1 
leak per day w ith a two-sided  0.05 significance level .  The sample  size assumes  a 
10% loss to follow -up over the 3-months of  treatment.  
3-9-6 Analysis Sets  
Efficacy analyses will be generated for the ITT, PP  and Responder analysis sets,  with 
the analysis on the Responder  set being the primary analysis. Safety analysis will be 
perfo rmed on the safety analysis set.  
1) Responder: The subset of PP who achieve at least a 50% reduction in leakage 
epi[INVESTIGATOR_671999] . 
2) Safety: All subjects  implanted with the device .   
3) Intent -to-Treat (ITT): All enrolled  subjects  meeting the inclusion criteria of the 
study who are not ineligible because of exclusion criteria; this is a secondary  
analysis population for the efficacy endpoints  and a primary analysis population 
for the safety endpoints . Missing outcome data will be handled per 3-9-9. 
4) Per-Protocol (PP): The subset of ITT subjects who comp lete the [ADDRESS_908082] 
activation  follow -up period.  
3-9-7 Exploratory Subgroup Analyses  
Subjects who respond to treatment (i.e. who achieve at least a 50% reduction in number 
of leak s from baseline to three months post -activation ) will be compared to non-
responders in terms of baseline characteristics and demographics  as described in the 
statistical analysis plan .  Efficacy endpoints will be analyzed for the responder subset.  
3-9-8 Calculation of Efficacy Variables  
Change in Incontinent Epi[INVESTIGATOR_1841] :  Incontinen t epi[INVESTIGATOR_1841] (IE) are measured  
prospectively  using [ADDRESS_908083] -activation of the eCoin system . 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 48 of 83  
Change in Severity and Frequency of Leakage :  Severity and frequency of leakage is 
measured  prospectively  using [ADDRESS_908084] -activation of the eCoin system . 
Change in Frequency :  Frequency of urination is measured  prospectively  using [ADDRESS_908085] -activation of the 
eCoin system . 
Change in Voided Volume:   Voided volume is measured  prospectively  using a urine 
collection tool and captured using  3-day voiding  diaries  administered  at baseline, 1, 2, 3, 
4, and [ADDRESS_908086]-activation of the eCoin system . 
Change in Quality of Life:   Quality of life is measured  prospectively  using the I -QoL 
questionnaires administered  at baseline, 1, 2, 3, [ADDRESS_908087] -activation of the 
eCoin system . 
Patient Global Impression of I mprovement : The level of patient satisfaction with the 
eCoin neuromodulation system will be rated by [CONTACT_1175] a descriptive scale of very 
much worse, much worse, worse, about the same, better, much better, and very much 
better.  
Patient Reported Satis faction : The level of patient satisfaction with the eCoin 
neuromodulatio n system will be rated by [CONTACT_1175] a scale of 1 to 5 where 1 is Not 
at All Satisfied, 2 is Slightly Satisfied, 3 is Somewhat Satisfied, 4 is Very Satisfied and 5 
is Completely Sa tisfied.  
3-9-9 Missing Outcome Data  
Due to device implantation, few patient drop -outs are expected through primary and 
secondary endpoints .  Careful clinical planning that minimizes patien t dropouts will be 
implemented.   
Multiple  imputation per the statistical analysis plan will be used for missing data . 
3-9-10 Safety  Analysis  
All AEs will be coded using  the Medical Dictionary for Regulatory Activities (MedDRA). 
The terms included in the tabulations will be organ system and preferred terms.  
Tabulat ions of general AEs will be provided by [CONTACT_672020], and will 
include the number of subjects exposed, the number of subjects with at least one AE, 
and the number of subjects with at least one AE by [CONTACT_672021]. 
These t abulations will be repeated for all AEs recorded as having a causal relationship 
to investigational product. Tabulations of local  AEs will be provided at [ADDRESS_908088]’s confidentiality is maintained on the CRFs 
or other documents submitted to the Sponsor. Subjects should be identified by [CONTACT_11703] a subject study number only.  Documents that are not for submission to the 
Sponsor such as the signed informed consent forms should be kept in strict confidence 
by [CONTACT_737].  In compliance  with ICH GCP Guidelines , it is required that the 
Investigator  and institution permit authorized representatives of the company, of the 
regulatory agency(s), and the IRB direct access to review the subject’s original medical 
records for verification of stu dy-related procedures and data.  Direct access includes 
examining, analyzing, verifying and reproducing any records and reports that are 
important to the evaluation of the study.  The Investigator  will inform and obtain the 
consent of the subject to permit  named representatives to have access to his/her study -
related records without violating the confidentiality of the subject.  Information about 
study subjects will be kept confidential and managed according to the requirements of 
the clinical sites regulat ory authority.   As a part of the consent process, subjects will sign 
an authorization informing the  following:  
 What protected health information (PHI) will be collected from subjects in this study  
 Who will have access to that information and why  
 Who will use or disclose that information  
 What rights does  a research subject have to revoke their authorization for use of 
their PHI  
3-10-2 Training  
All study forms  and procedures  will be reviewed with medical/study staff at the 
participating  center s.  Investigators or surgical designee will also be medically trained 
and certified by [CONTACT_11704].   Training will include any 
combination of cadaver training, video, or supervised procedures.  To perform the 
procedure the Investigator  or designated medical doctor will need to be experienced in 
urology or uro -gynecology , and be certified by [CONTACT_1034].  
3-10-3 Documentation, Case Report Forms and Source Documents  
All documents will be signed off by [CONTACT_672022], with each document identified with a document number and 
revision code.  Investigators will maintain the following items of documentation in the 
Investigator’s Study File  on site : 
 Protocol and any amendments  
 Consent form s (sample, and subject signed and dated)  
 IRB/ERC  approval for the protocol  and consent form  
 Agreement letter sent to Sponsor  
 Case Report Forms   
 Adverse event or Problem reports to Sponsor and IRB  
 Inventory control log  
 Enrollment Log  
 Records of deviations, violations, and amendments  
 Implant Registration Cards, where required by [CONTACT_672023]:  All data requested on the CRF must be recorded.  All missing data 
must be explained.  If a space on the CRF is left blank because the procedure wa s not 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-[ADDRESS_908089] “N/D”.  If the item is not applicable to 
the individual case, select “N/A”.  If any entry error has been made, to correct such an 
error, draw a single straight line through the incorrect entry and enter  the correct data 
above it.  All such changes must be initialed and dated.  DO NOT ERASE OR WHITE 
OUT ERRORS.  Case Report Forms will be kept in the Study File.  
Source Documents:   medical records, voiding diaries, QoL questionnaires , etc. will be 
maintaine d at the study clinic . 
3-10-[ADDRESS_908090]  (see 4-7).  The Sponsor is responsible for managing the device 
accountability log acro ss the study.  Each site will have a device tracker to be reconciled 
at the conclusion of the study.  
3-10-[ADDRESS_908091] operating procedures based on Good Clinical Practice and 
other applicable Federal regulations.  
The monitor’s responsibilities are:  
 
 Conduct Site Initiation visit ( after IRB approval/ before first subject enrollment).  
 Conduct periodic monitoring visits.  
 Compare case report forms to source documents.  
 Review Investigator ’s files for accuracy, currency, and completeness.  
 Ensure that informed consents are obtained.  
 Ensure that IRB review is current.  
 Ensure protocol compliance, docu ment deviations.  
 Prepare reports of visits.  
 Ensure adverse events are reported.  
 Conduct closeout visit (after all case report forms are received in house).  
 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-[ADDRESS_908092] or the 
scientific validity of the results . 
1) A Physician Investigator can deviate from the protocol in an emergency situation, 
such as when a departure from the protocol is required to protect the life or 
physica l well -being of a participant.  The Sponsor and the IRB/Ethics Committee  
must be notified as soon as possible, but not later than 5 days after the 
emergency situation occurred.  
2) Any non-emergency, major deviation  to the protocol must be approved by [CONTACT_11707]/Ethics Committee  prior to implementation.  If a major 
deviation occurs that is not in response to the protection of a subject, without 
prior approval, the event is considered non -compliance.  Non -compliance must 
be reported to the IRB/Ethics Committee promptly – no later than 5 days after the 
deviation.  A PI’s failure to report promptly any major deviation for which the PI 
[INVESTIGATOR_314072] -compliance and will be 
evaluated by [CONTACT_672024].  
3-10-6-[ADDRESS_908093] or the 
scientific validity of the results. If a minor deviation from the protocol is discovered, it 
should be noted on the protocol deviation log at the site and brought to the attention of 
the monitor at the next CRA visit.  These deviations do not need to be reported to the 
IRB/Ethics Committee .  Examples of a minor protocol deviation:  
1) Follow -up visits that occurred outside the protocol required time frame because 
of the participant’s schedule.  
2) Study procedure conducted out of timeframe, e.g. 3-day diary  
3) Participant failure to initial every page of the consent form  
4) Participant  failure to return patient diary  
5) Copy of the ICF not given to the participant  
6) Missing original signed consent, but a copy exists  
7) Patient not given implant card  
3-10-6-[ADDRESS_908094] be 
brought to the attention of the Sponsor.   
3-10-6-4 Statement of Clinical C ompliance  
The study will be conducted in accordance with the design a nd specific provisions of this 
IRB/Ethics Committee  approved protocol, in accordance with the ethical principles that 
have their origin in the Declaration of Helsinki, and that are consis tent with Good Clinical 
Practice (GCP) and the applicable regulatory requirement(s). The Investigator will 
assure that no deviation from, or changes to, the protocol will take place without prior 
agreement from the Sponsor and documented approval from the IRB/Ethics Committee , 
except where necessary to eliminate an immediate hazard(s) to the trial participants. 
The Investigator will promptly report to the IRB/Ethics Committee  and the Sponsor any 
changes in research activity and all unanticipated problems in volving risk to human 
subjects, or others.  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-[ADDRESS_908095] information  
 
Name [CONTACT_11717]:  Valencia Technologies Corporation  
Address:  [ADDRESS_908096] Person:  Dave Peterson, Chief Technology Officer   
Telephone Number:  (661) 775 -1414  
Fax Number:  (661) 775 -1411  
3-11-1-2 Manufacturer compliance with Subpart C, Design Controls 
(section 820.30), the Quality System Regulations (21 CFR Part 820)  
The eCoin Subcutaneous Neuromodulation System is manufactured by [CONTACT_11708] [ADDRESS_908097] to ensure the eCoin device is 
produced in accordance with the design and performance specifications  (attachment 4-
23). Each device is tracked individually by [CONTACT_11709] a device history record.  
3-11-1-[ADDRESS_908098] signed an 
Investigator Agreement, a template  of which is enclosed as Attachment 4-21 in 
compliance with § 812.43. New U.S. based Principal  Investigators w ill be required to 
sign the Investigator Agreement before being added to the study. Attachment 4-[ADDRESS_908099] of investigators.  
Sponsor  
Valencia Technologies Co rporation  
Stacy Chambliss, Tel: +1 (661)[ADDRESS_908100] / Ethics Committees  
Institutional Review Bo ard / Ethics Committees will approve  the protocol for each 
respective  center pursuant to center requirements or under an independent review 
board . 
 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 54 of 83 3-12-4 Roles and Responsibilities  
3-12-4-1 Investigator  
The following are the responsibilities of the Investigator : 
1) Assure IRB/Ethics Committee  approval of protocol and informed consent is 
obtained.  
2) Follow the study protocol . 
3) Permit monitor to inspect facilities and records . 
4) Permit regulatory inspections of facilities and records, if necessary . 
5) Inform a patient of any risks and benefits associated with use of the device , and 
obtain the patient’ s written consent for its use . 
6) Enroll subjects, execute study, transcribe data from source documents to Case 
Report Forms . 
7) Submit annual progress reports, final reports, and adverse event reports to 
IRB/Ethics Committee  and to Sponsor . 
8) Return unused study articles, record their receipt, disposition, and return  
9) Refrain from promoting study or study articles  in any manner  that is not Sponsor 
authorized . 
10) Conduct study in accordance with the protocol . 
11) Track Sponsor prov ided inventory and assignments  
12) Maintain medical histories of subjects . 
13) Retain records for 10 years  or as required by [CONTACT_11710] . 
3-12-4-2 IRB/Ethics Committee  
The following are the responsibilities of the IRB or Ethics Committee, where one group 
will be designated by [CONTACT_672025] : 
1) Review and approve, modify, or disapprove the study protocol and informed 
consent form . 
2) Receive continuing and f inal reports on study progress.  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 55 of 83 3-12-4-3 Sponsor  
The following are the responsibilities of the Sponsor:  
1) Submit protocol and informed consent to IRB/Ethics Committee  and FDA and 
await  approval . 
2) Submit proposed amendments to the protocol and informed consent to 
IRB/Ethics Committee  and Regulatory Authority (where applicable and await 
approval, unless the chang e reduces the risk to subjects ). 
3) Assure IRB/Ethics Committee  and Regulatory Approval (where applicable) is 
obtaine d. 
4) Select and train monitors . 
5) Select and train Investigator s and study personnel . 
6) Obtain agreement letter and c.v. of Investigator (s). 
7) Control  shipment of test and control articles . 
8) Conduct overall administration of study . 
9) Investigate unanticipated, device -related adverse events . 
10) Document protocol deviations and violations . 
11) Report and respond to the DSMB . 
3-12-[ADDRESS_908101]  Compensation  
Subjects will not be paid for participation in this study. However they will be provided a 
small stipend  for travel and accommodation expenses associated with the study 
treatment and follow -up requirements.  
  Study Timetable  
Study initiation is planned for April 2017 . Study enrollment of 100 subjects  (to implant 50 
subjects)  is expected to be completed by [CONTACT_61763] [ADDRESS_908102] 2018 . 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 56 of 83 4 Attachments  
  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 57 of 83 
 3-day Voiding Diary  
  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 58 of 83 
 Manuals, and Labels  
 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 59 of 83 
 Investigator’s Brochure  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-[ADDRESS_908103] 
 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 64 of 83 
 Case Report Form s 
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 65 of 83 
 Adverse Event  Form  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 66 of 83 
 DSMB Charter  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 67 of 83 
 OUS Study for H ypertension Protocol  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 68 of 83 
 OUS Study for Hypertension CRFs for Infections  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 69 of 83 
 OUS Study for Hypertension DSMB Letter Recommending 
Suspension of Implantation at Site 12  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 70 of 83 
 SNS Risk Assessment (110 -1493)  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-[ADDRESS_908104] of Investigators  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 82 of 83 
 303-1122 Software Design Specification SNS  
 
Original Application for an Investigational Device Exemption  
Subcutaneo us Tibial Nerve Stimulation for Urinary Urge Incontinence     
_____________________________________________________________________________  
Valencia Technologies Corporation          Doc. No. 111-3186 Rev. 1.6                         
CONFIDENTIAL                                               Page 83 of 83 
 Biocompatibility Reports  
 